Core Viewpoint - The announcement by Guangdong Tianen Pharmaceutical Co., Ltd. regarding the acceptance of the registration application for Lidocaine and Prilocaine aerosol marks a significant advancement in the research and commercialization of sexual health medications [1]. Group 1: Product Development - Tianen's subsidiary, Shandong Huabo Kaisheng Biotechnology Co., Ltd., received the acceptance notice from the National Medical Products Administration for the aerosol product [1]. - The original drug was developed by Plethora Solutions in the UK and has been commercially promoted in major European markets since 2013, transitioning from prescription to over-the-counter status in 2020 [1]. Group 2: Product Advantages - The aerosol formulation offers advantages over oral medications like Dapoxetine, including ease of use, higher patient compliance, rapid onset of action, and reduced side effects associated with oral drugs [1]. - The product has been validated through over ten years of clinical use in overseas markets, confirming its efficacy and safety [1]. Group 3: Market Positioning - Tianen has a strong brand foundation and channel advantages in the sexual health sector, with its core product "Aiting Jiu" (Dapoxetine) having established a comprehensive sales network [1]. - The successful launch of the aerosol could leverage the brand effect and channel resources of the "Aiting Jiu" series to quickly penetrate the market and enhance the company's competitive position in the sexual health business [2].

Core Viewpoint - The announcement indicates that TianKang's subsidiary, Shandong Huabo Kaisheng Biotechnology Co., Ltd., has received a notice of acceptance for the registration application of Lidocaine and Prilocaine aerosol from the National Medical Products Administration (NMPA) of China [1] Group 1 - The application for the drug registration has been accepted by the NMPA based on the provisions of Article 32 of the Administrative Licensing Law of the People's Republic of China [1]

Earnings Forecasts - Shengyi Electronics expects a net profit of 1.431 billion to 1.513 billion yuan in 2025, an increase of 331.03% to 355.88% year-on-year [1] - Tigermed anticipates a net profit of 830 million to 1.23 billion yuan in 2025, representing a growth of 105% to 204% year-on-year [2] - Shunbo Alloy forecasts a net profit of 210 million to 270 million yuan in 2025, with an increase of 222.96% to 315.23% year-on-year [3] - Jinkong Electric expects a net profit of 155 million to 195 million yuan in 2025, reflecting a growth of 383.21% to 507.9% year-on-year [9] - Baiao Saitu anticipates a net profit of 162 million to 182 million yuan in 2025, with a year-on-year increase of 384.26% to 443.88% [18] - Panjiang Co. expects a net profit of 318 million to 380 million yuan in 2025, representing a growth of 205.30% to 264.83% year-on-year [38] Loss Forecasts - Liaoning Energy predicts a net loss of 273 million to 410 million yuan in 2025, compared to a profit of 202 million yuan in the previous year [5] - Anbotong anticipates a net loss of 114 million to 165 million yuan in 2025, with a revenue decrease of 19.65% to 27.25% [7] - Wantai Bio forecasts a net loss of 330 million to 410 million yuan in 2025, compared to a profit of 106 million yuan in the previous year [12] - Xingyun Co. expects a net loss of 155 million to 230 million yuan in 2025, compared to a loss of 82.44 million yuan in the previous year [20] - Huaxing Co. anticipates a net loss of 800 million to 1.2 billion yuan in 2025, with a reduction in loss compared to 1.67 billion yuan in the previous year [46] New Product Approvals - Hengrui Medicine received acceptance for a new indication application for its innovative drug, combining Carrelizumab and Apatinib for treating unresectable liver cancer [4] - Tianen Kang's subsidiary received a drug registration acceptance notice for Lidocaine and Prilocaine aerosol [31] - Lisheng Pharmaceutical announced that its Aminophylline tablets passed the consistency evaluation for generic drugs [40] Share Buyback Plans - Hengyuan Coal Power plans to repurchase shares with a total amount not less than 200 million yuan and not exceeding 250 million yuan [13] Contract Wins - China Communication Signal Co. won contracts totaling approximately 5.26 billion yuan for 21 important projects in the railway and urban rail transit markets [37]

Group 1 - The company Tiancong announced that it will accept investor research from Da Cheng Fund Management Co., Ltd. on January 29, 2026, with the participation of Mr. Li Ting, the company's director, vice president, and board secretary [1] Group 2 - The investigation into the "Jie Wo Rui" redemption crisis on the Shuibei Gold platform revealed a 40-fold leverage bet, indicating that the platform incurs losses as gold prices rise [1] - Investors reported that the proposed redemption plan offers a principal repayment at a 20% discount, which they find unacceptable [1]

Core Viewpoint - The company TianKang has indicated that the development progress of the rosacea indication is faster than that of pediatric vitiligo, and it is expected to be the first indication for CKBA to submit a registration application [1] Group 1: Development Progress - The rosacea indication has over 50 million patients in China with a strong willingness to pay [1] - The company aims to complete Phase III clinical trials by the end of 2027 [1] Group 2: Market Opportunity - There are currently few innovative drug developments globally for this indication [1] - If clinical data is favorable, the drug could become the first Class 1 innovative drug for this indication in China [1]

Core Viewpoint - The company announced that its wholly-owned subsidiary, Shandong Huabo Kaisheng Biotechnology Co., Ltd., has received the acceptance notice for the registration application of Lidocaine Prilocaine aerosol from the National Medical Products Administration of China [1] Group 1 - The National Medical Products Administration has reviewed and accepted the drug registration application for the aerosol product [1] - The acceptance is based on the provisions of Article 32 of the Administrative Licensing Law of the People's Republic of China [1]

证券代码：301263 证券简称：泰恩康 公告编号：2026-009 广东泰恩康医药股份有限公司 关于全资子公司利多卡因丙胺卡因气雾剂收到药品 注册受理通知书的公告 一、申请注册药品的基本情况 药品名称：利多卡因丙胺卡因气雾剂 申请事项：境内生产药品注册上市许可 许可药品注册分类：化学药品 3 类 申请人：山东华铂凯盛生物科技有限公司 审核结论：根据《中华人民共和国行政许可法》第三十二条的规定，经审 查，决定予以受理。 二、药品相关情况简介 利多卡因丙胺卡因气雾剂的原研药物由英国 Plethora Solutions 公司开发， 2013 年在欧盟批准上市，已在欧洲主要市场商业推出， 2020 年获得欧盟委员 会批准，由处方药转为非处方药，目前国内尚未进口。不同于勃起功能障碍有 诸多药物获批上市，国内当前获批用于早泄治疗的药物只有达泊西汀，其他药 物治疗都是适应症外按需使用。利多卡因丙胺卡因气雾剂作为全球范围内第二 款获批用于早泄治疗的药物，在国外有 10 余年的使用经验，其疗效在临床试验 研究及实际应用中得到验证，公司研发的利多卡因丙胺卡因气雾剂的质量、疗 本公司及董事会全体成员保证公告内容的真实、准确和完 ...

Group 1: Investor Relations Activity - The investor relations activity involved specific targeted research with participation from various fund management companies and securities firms [2][3]. - The meeting was held online on a Thursday morning, with a duration of 50 minutes [2]. Group 2: Employee Stock Ownership Plan - The company disclosed a draft for an employee stock ownership plan aiming to raise a total of CNY 33.608 million, involving directors, senior management, and core employees [3]. - The performance assessment period for the plan is set from 2026 to 2028, with specific revenue and profit targets: - Revenue targets: CNY 1 billion in 2026, CNY 1.5 billion in 2027, and CNY 2 billion in 2028 - Profit targets: CNY 300 million in 2026, CNY 500 million in 2027, and CNY 800 million in 2028 [3][4]. Group 3: Product Development and Market Strategy - The company has several core products expected to be approved or submitted for approval, including "Aitinglie" and "Lidocaine" aerosol, with anticipated revenue growth from existing products and new approvals [4][5]. - The company is actively promoting the "Hewei Zhengchang Wan" product through various media channels and expanding its sales through clinics and online platforms [5][8]. - The company plans to enhance brand promotion and has established a dedicated team for third-party channels, focusing on clinics and internet hospitals [8]. Group 4: Alzheimer's Disease Research - The company is developing CKBA for Alzheimer's disease, which has shown promising results in animal models, including cognitive improvement and reduced neuroinflammation [6][7]. - CKBA's mechanism targets MFE-2, a key enzyme in lipid metabolism, which is crucial for maintaining the homeostasis of microglial cells [7]. Group 5: Clinical Trials and Market Potential - The company is prioritizing the registration of treatments for pediatric vitiligo and rosacea, with rosacea expected to progress faster due to a shorter treatment cycle [9][10]. - The domestic market for pediatric vitiligo is significant, with no existing treatments approved by the FDA, indicating potential for market expansion [11]. Group 6: Forward-Looking Statements - The report includes forward-looking statements regarding future plans and performance forecasts, emphasizing the need for investors to recognize associated risks [11].

Group 1 - The company expects a net profit attributable to shareholders for the fiscal year 2025 to be between 25 million to 35 million yuan, representing a year-on-year decline of 67.66% to 76.90% [1] - The net profit after deducting non-recurring gains and losses is projected to be between 27 million to 37 million yuan, reflecting a year-on-year decrease of 65.11% to 74.54% [1] - The decline in performance is primarily attributed to intense market competition in the core sector of sexual health and a decrease in sales revenue [1] Group 2 - The core product "He Wei Zheng Chang Wan" is affected by insufficient production capacity and delays in imports [1] - Increased investment in research and development and brand promotion has led to a rise in selling expenses, thereby compressing profit margins [1]

Core Viewpoint - The company has announced an employee stock ownership plan (ESOP) for 2026, aiming to incentivize up to 145 individuals, including directors and key employees, with a total funding cap of 33.608 million yuan [1] Group 1: Employee Stock Ownership Plan - The ESOP will be funded through employees' legal salaries and self-raised funds, with no financial assistance or loan guarantees provided by the company [1] - The repurchase price for the shares is set at 16.93 yuan per share, with a maximum of 1.9851 million shares to be held, representing approximately 0.47% of the total share capital [1] - Performance targets for the years 2026 to 2028 have been established, with revenue and profit goals progressively increasing each year [1] Group 2: Performance Assessment and Goals - For 2026, the revenue target is set at 1 billion yuan, with a trigger value of 900 million yuan; the profit target is 300 million yuan, with a trigger value of 270 million yuan [1] - The revenue target for 2027 increases to 1.5 billion yuan (trigger value: 1.35 billion yuan), and the profit target rises to 500 million yuan (trigger value: 450 million yuan) [1] - By 2028, the revenue target reaches 2 billion yuan (trigger value: 1.8 billion yuan), and the profit target is set at 800 million yuan (trigger value: 720 million yuan) [1] Group 3: Unlocking Rules and Strategic Goals - If either revenue or profit meets the target, the unlocking ratio is 100%; if both meet the trigger values but not the targets, the unlocking ratio is 90% [2] - The ESOP aims to establish a profit-sharing mechanism between employees and the company, enhancing team stability and competitiveness to support long-term strategic goals [2] Group 4: Product Pipeline and Market Position - The company has received approval for a Phase II clinical trial of its core product, CKBA cream, targeting pediatric vitiligo, with patient enrollment expected to start in Q1 2026 [2] - The company anticipates approvals for its generic drugs, including compound sodium sulfate tablets and a unique gastrointestinal product, in the first half of 2026, with another eye medication expected in the second half [2] - The company forecasts continued growth in its sexual health segment, driven by brand promotion and the launch of new products [3]